Penumbra Inc (NYSE:PEN) CFO Sells $625,679.58 in Stock

Penumbra Inc (NYSE:PEN) CFO Sridhar Kosaraju sold 6,026 shares of the company’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $103.83, for a total transaction of $625,679.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Sridhar Kosaraju also recently made the following trade(s):

  • On Wednesday, November 22nd, Sridhar Kosaraju sold 2,600 shares of Penumbra stock. The stock was sold at an average price of $105.99, for a total transaction of $275,574.00.
  • On Friday, November 24th, Sridhar Kosaraju sold 4,818 shares of Penumbra stock. The stock was sold at an average price of $105.10, for a total transaction of $506,371.80.
  • On Friday, November 17th, Sridhar Kosaraju sold 4,290 shares of Penumbra stock. The stock was sold at an average price of $103.52, for a total transaction of $444,100.80.
  • On Monday, November 20th, Sridhar Kosaraju sold 21,956 shares of Penumbra stock. The shares were sold at an average price of $105.27, for a total transaction of $2,311,308.12.
  • On Wednesday, November 15th, Sridhar Kosaraju sold 10,900 shares of Penumbra stock. The shares were sold at an average price of $105.89, for a total transaction of $1,154,201.00.

Shares of Penumbra Inc (NYSE:PEN) traded down $1.90 during trading on Monday, hitting $98.50. 171,700 shares of the stock were exchanged, compared to its average volume of 191,239. Penumbra Inc has a 1-year low of $62.43 and a 1-year high of $116.35.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.07. The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $79.17 million. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The company’s revenue for the quarter was up 24.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.04) EPS. sell-side analysts forecast that Penumbra Inc will post -0.15 earnings per share for the current year.

PEN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, August 30th. Canaccord Genuity upped their price objective on shares of Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets upped their price objective on shares of Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Finally, BidaskClub cut shares of Penumbra from a “buy” rating to a “hold” rating in a research report on Friday, August 18th.

Several institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Penumbra by 10.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock worth $102,000 after acquiring an additional 114 shares during the period. Verition Fund Management LLC acquired a new stake in Penumbra during the second quarter worth about $213,000. Teacher Retirement System of Texas acquired a new stake in Penumbra during the third quarter worth about $214,000. Ameritas Investment Partners Inc. raised its stake in Penumbra by 10.8% during the second quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock worth $226,000 after acquiring an additional 250 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in Penumbra during the second quarter worth about $252,000. Institutional investors and hedge funds own 71.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/11/penumbra-inc-pen-cfo-sells-625679-58-in-stock.html.

Penumbra Company Profile

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply